biomarkers
13 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Rescooped by Arundhati (Ari) Rao from Breast Cancer News
Scoop.it!

New blood test may aid in early detection of breast cancer

New blood test may aid in early detection of breast cancer | biomarkers | Scoop.it

"A new blood test for peptides cleaved by carboxypeptidase N may soon be available to help detect early stages of breast cancer.

Carboxypeptidase N, an enzyme that modifies proteins to produce smaller peptides, is elevated in lung cancer. A new study in Clinical Chemistry (2013; doi:10.1373/clinchem.2013.211953) showed that enzyme levels are also increased in breast cancer patients. Further, peptide levels in the blood accurately predicted the presence of early-stage breast cancer tissue in mice as well as a small population of human patients. 

"In this paper we link the catalytic activity of carboxypeptidase N to tumor progression in clinical samples from breast cancer patients and a breast cancer animal model," said project leader Tony Hu, PhD, a biomedical engineer in the Department of Nanomedicine at Methodist Hospital Research Institute, Houston, Texas. "Our results indicate that circulating peptides generated by carboxypeptidase N can serve as clear signatures of early disease onset and progression."

Currently, there are no quick and inexpensive laboratory tests for the detection of breast cancer. The American Cancer Society recommends that healthy women age 40 years and older have a mammogram every year, and that healthy women younger than 40 years have a clinical breast exam every 3 years for breast cancer screening.

"We are trying to create a noninvasive test that profiles what's going on at a tissue site without having to do a biopsy or costly imaging," Hu said. "…This could be better for patients and a lot cheaper than the technology that exists…[the] materials only cost about $10 per test."


Via Curated by A4BC.ORG
more...
Scooped by Arundhati (Ari) Rao
Scoop.it!

British Journal of Cancer - The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients

British Journal of Cancer - The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients | biomarkers | Scoop.it
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible.
Arundhati (Ari) Rao's insight:

ExpressionExpression levels of ER realed genes may predict late distant mets in ER positive breast cancer better than oncotype dX test?

more...
No comment yet.
Scooped by Arundhati (Ari) Rao
Scoop.it!

Cancer trial drug eliminates advanced leukaemia in 23% of patients - The Guardian

Cancer trial drug eliminates advanced leukaemia in 23% of patients - The Guardian | biomarkers | Scoop.it
The Guardian Cancer trial drug eliminates advanced leukaemia in 23% of patients The Guardian They say the cancer was cleared in 23 per cent of patients and a further 61 per cent achieved partial remission, despite having endured an average of four...
more...
No comment yet.
Rescooped by Arundhati (Ari) Rao from Breast Cancer News
Scoop.it!

Novel agent set for unique clinical test in inflammatory breast cancer

Novel agent set for unique clinical test in inflammatory breast cancer | biomarkers | Scoop.it

"A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.

The finding, published online this month in the Journal of Experimental Therapeutics and Oncology, has led to development of a phase 1/2 clinical trial at Kimmel Cancer Center to test the agent, Romidepsin (Istodax), in combination with nab-paclitaxel (Abraxane) chemotherapy for advanced inflammatory breast cancer (IBC).

"Because this kind of breast cancer is very difficult to treat, we hope this new combination of anticancer agents will change the outcome of this aggressive disease," says the study's senior investigator, Massimo Cristofanilli, M.D., F.A.C.P., Professor of Medical Oncology and Director of the Jefferson Breast Care Center.

The study was conducted in collaboration with the lead author, Fredika Robertson, Ph.D., at The University of Texas M. D. Anderson Cancer Center, and was supported by a Promise Grant from the Susan G Komen Foundation awarded to Drs. Cristofanilli and Robertson in 2008."


Via Curated by A4BC.ORG
more...
Scooped by Arundhati (Ari) Rao
Scoop.it!

Cancer progress threatened by budget cuts in Congress, group says - NBCNews.com

Cancer progress threatened by budget cuts in Congress, group says - NBCNews.com | biomarkers | Scoop.it
Cancer progress threatened by budget cuts in Congress, group says
NBCNews.com
Nine new cancer drugs approved in just one year. A speedy new process for approving drugs that gets breakthrough treatments to cancer patients faster.
more...
No comment yet.